NEW YORK – Viome Life Sciences said Tuesday that it has raised $25 million in a Series D funding round.

纽约——维奥姆生命科学公司周二表示，它已在D轮融资中筹集了2500万美元。

Investors for the round included Khosla Ventures, Bold Capital, WRG Ventures, Marc Benioff, and other existing investors. The firm will use the money to help launch the company's diagnostic division, expand its testing menu, and hire Kal Raman as the firm's chief operating officer to lead those projects..

本轮投资者包括科斯拉风险投资公司、博尔德资本、WRG风险投资公司、马克·贝尼奥夫和其他现有投资者。该公司将利用这笔资金帮助启动公司的诊断部门，扩大其测试菜单，并聘请卡尔·拉曼（KalRaman）担任公司首席运营官，领导这些项目。。

The firm noted that Raman previously worked as a senior VP of non-media business at Amazon, chief digital officer at Samsung, and chief operating officer at Groupon.

该公司指出，拉曼曾担任亚马逊（Amazon）非媒体业务高级副总裁、三星（Samsung）首席数字官和Groupon首席运营官。

Viome said that it plans to expand its diagnostic offerings beyond its tests for oral and throat cancers, and Raman will lead efforts to develop tests for the early detection of other cancers, chronic diseases, and aging-related conditions. The firm said that it is positioned to launch a suite of new tests, such as tests for gut health conditions including irritable bowel syndrome and inflammatory bowel disease..

Viome表示，它计划将其诊断产品扩展到口腔癌和喉癌检测之外，Raman将牵头开发用于早期发现其他癌症、慢性疾病和衰老相关疾病的检测方法。该公司表示，它将推出一系列新的测试，例如肠道健康状况测试，包括肠易激综合征和炎症性肠病。。

Viome recently said that it inked a distribution deal with Henry Schein for its Oral Health Pro With CancerDetect laboratory-developed test that is used for the detection of oral and throat cancers. Using RNA sequencing and AI to measure gene expression of the oral microbiome and human cells in saliva, the assay identifies early biomarkers associated with oral and throat cancer.

Viome最近表示，它与Henry Schein就其口腔健康专业人员与CancerDetect实验室开发的用于检测口腔癌和喉癌的测试达成了分销协议。使用RNA测序和AI测量唾液中口腔微生物组和人类细胞的基因表达，该测定法可鉴定与口腔癌和喉癌相关的早期生物标志物。

The firm also said last year that it raised $86.5 million in an oversubscribed Series C round that would support the development of the firm's testing portfolio and expansion into retail sales.

该公司去年还表示，它在C轮超额认购中筹集了8650万美元，这将支持该公司测试组合的发展和向零售业的扩张。